Basmisanil
Basmisanil (; developmental codes RG-1662 and RO5186582) is a highly selective inverse agonist/negative allosteric modulator of α5 subunit-containing GABAA receptors which is under development by Roche for the treatment of cognitive impairment associated with Down syndrome. As of June 2016, it is no longer studied. It is studied with schizophrenia patients. See also * List of investigational antipsychotics This is a list of investigational antipsychotics, or antipsychotics that are currently under development for clinical use but are not yet approved. ''Chemical/generic names are listed first, with developmental code names, synonyms, and brand names ... * GABAA receptor negative allosteric modulator * GABAA receptor § Ligands References External links Basmisanil - AdisInsight Fluoroarenes GABAA receptor negative allosteric modulators Nicotinamides Nootropics Isoxazoles {{Nervous-system-drug-stub ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]